Download this slideset to review the latest clinical data supporting the optimal use of biomarker testing for checkpoint inhibitor therapy in patients with advanced NSCLC, unresectable stage III NSCLC, or extensive-stage SCLC.
Download this slideset to review expert guidance on optimal biomarker testing in lung cancer, including molecular testing by NGS and PD-L1 testing to predict response to checkpoint inhibitor–based therapy.
Download this slideset to gain expert insights on promising new biomarkers predicting response to checkpoint inhibitors in lung cancer, including thoughts on TMB, MSI, and immunogenic neoantigen burden.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.